SONE-333 represents a significant evolutionary step in KRAS-directed therapy. By combining optimized covalent binding kinetics, a structure designed to evade common resistance mutations, and proven CNS penetration, it addresses the major shortcomings of first-generation KRAS G12C inhibitors. Pending successful translation in Phase I/II clinical trials, SONE-333 has the potential to establish a new standard of care for patients with KRAS G12C-mutant malignancies.
Not registered yet?
Register now! It is easy and done in 1 minute and gives you access to special discounts and much more!